System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Studies

Observational Recruiting

NCT05899309 on ClinicalTrials.gov

Precision Medicine to Predict the Trajectory of Liver Cirrhosis: Prospective Cohort Study

Official title: Precision Medicine to Predict the Trajectory of Liver Cirrhosis : Prospective Cohort Study

  • Sponsor: Changi General Hospital
  • Enrollment: 80 (Estimated)
  • Study start: 2022-05-23 (Actual)
  • Primary completion: 2023-12-12 (Estimated)
  • Study completion: 2024-09-01 (Estimated)
  • Allocation: N/a
  • InterventionModel: N/a
  • Masking: None
  • PrimaryPurpose: Other

Brief Summary

Preventing decompensation is a key endpoint in the management of compensate cirrhosis patients. The known factors that increases the risk of decompensation include the presence of clinically significant portal hypertension (CSPH) and the control of primary etiology of cirrhosis. Other factors which may influence the progression of cirrhosis included the presence of metabolic syndrome (diabetes mellitus and obesity), frailty, concomitant medications (statin, non-selective beta-blocker) were not well understood. Investigators aim to perform a pilot, observational study to study various baseline factors in relation to the clinical outcome of cirrhosis patients in a prospective follow up.

Conditions

  • Liver Cirrhosis
  • Metabolic Syndrome
  • Spleen; Fibrosis
  • Frailty

Intervention / Treatment

  • Diagnostic Test: liver and spleen stiffness test and laboratory test

Primary Outcome Measures

  • Liver related events (3 years)
    Determine the rate of liver related events with and without metabolic syndrome

Countries

Singapore

Locations and Investigators

  • Changi General Hospital, Singapore, Singapore (Recruiting)
    • Ann Cheung, MSc
    • Siew Yoon Yap, BSc

Study Officials